Skip to main content

2025 IDWeek Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Session Icons

Live Streamed

On Demand

Deanna Merrill, PharmD, MBA, AAHIVP

Medical Affairs Scientific Director, Research
ViiV Healthcare

Disclosure(s): ViiV Healthcare: employee

Poster(s):

(P-376) The US REGAL Cohort: A Retrospective Real-world Study of the Effectiveness and Tolerability of the Antiretroviral Treatment Regimens DTG/3TC Compared to BIC/FTC/TAF in Older Persons Living with HIV

Monday, October 20, 2025
12:15 PM - 1:30 PM US ET
(P-396) PREFER-LA: People with HIV (PWH) in the United States with Prior Adherence Challenges with Oral Antiretroviral Therapy (ART) Prefer Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA) Therapy after Switch

Monday, October 20, 2025
12:15 PM - 1:30 PM US ET